Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 2
1949 1
1951 1
1953 1
1956 1
1958 1
1959 1
1961 1
1964 2
1965 14
1966 42
1967 57
1968 96
1969 79
1970 103
1971 80
1972 91
1973 108
1974 134
1975 83
1976 87
1977 106
1978 90
1979 95
1980 100
1981 95
1982 122
1983 96
1984 123
1985 125
1986 142
1987 155
1988 158
1989 214
1990 251
1991 292
1992 260
1993 346
1994 304
1995 279
1996 284
1997 244
1998 218
1999 202
2000 209
2001 193
2002 207
2003 199
2004 208
2005 226
2006 245
2007 224
2008 265
2009 273
2010 290
2011 303
2012 313
2013 319
2014 363
2015 332
2016 338
2017 346
2018 360
2019 356
2020 373
2021 336
2022 366
2023 273
2024 327
2025 342
2026 43

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,080 results

Results by year

Filters applied: . Clear all
Page 1
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Becker MA, et al. N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373. N Engl J Med. 2005. PMID: 16339094 Free article. Clinical Trial.
Although the incidence of gout flares diminished with continued treatment, the overall incidence during weeks 9 through 52 was similar in all groups: 64 percent of patients receiving 80 mg of febuxostat, 70 percent of those receiving 120 mg of febuxostat, and 64 percent of those …
Although the incidence of gout flares diminished with continued treatment, the overall incidence during weeks 9 through 52 was similar in al …
Allopurinol toxicity.
Sergent JS. Sergent JS. South Med J. 1979 Nov;72(11):1359-60. doi: 10.1097/00007611-197911000-00003. South Med J. 1979. PMID: 505064 No abstract available.
Allopurinol.
Rundles W. Rundles W. N Engl J Med. 1969 Apr 24;280(17):961. doi: 10.1056/NEJM196904242801719. N Engl J Med. 1969. PMID: 5775639 No abstract available.
Allopurinol.
[No authors listed] [No authors listed] Br Med J. 1967 Feb 25;1(5538):483. Br Med J. 1967. PMID: 6017531 Free PMC article. No abstract available.
Allopurinol in dermatology.
Tsai TF, Yeh TY. Tsai TF, et al. Am J Clin Dermatol. 2010;11(4):225-32. doi: 10.2165/11533190-000000000-00000. Am J Clin Dermatol. 2010. PMID: 20509717 Review.
In dermatology, allopurinol is best known for its severe cutaneous adverse reactions. Recent genomic studies conducted in Taiwan have discovered useful HLA markers for determining the susceptibility of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with …
In dermatology, allopurinol is best known for its severe cutaneous adverse reactions. Recent genomic studies conducted in Taiwan have …
Allopurinol-induced DRESS syndrome.
Markel A. Markel A. Isr Med Assoc J. 2005 Oct;7(10):656-60. Isr Med Assoc J. 2005. PMID: 16259349 Free article. Review.
Complications, including renal calculi, uric acid nephropathy and gout, occur in a small proportion of patients. Allopurinol, an analog of hypoxanthine, has been widely used in clinical practice for over 30 years for the treatment of hyperuricemia and gout. ...A syndrome c …
Complications, including renal calculi, uric acid nephropathy and gout, occur in a small proportion of patients. Allopurinol, an anal …
Allopurinol.
Greene MI, Fujimoto WY, Seegmiller JE. Greene MI, et al. N Engl J Med. 1969 Apr 24;280(17):961. N Engl J Med. 1969. PMID: 5775640 No abstract available.
How to prevent allopurinol hypersensitivity reactions?
Stamp LK, Barclay ML. Stamp LK, et al. Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i35-i41. doi: 10.1093/rheumatology/kex422. Rheumatology (Oxford). 2018. PMID: 29272508 Review.
Allopurinol hypersensitivity syndrome (AHS) is a severe and sometimes life-threatening adverse drug reaction. ...A low starting allopurinol dose may reduce AHS risk, but the relationship between maintenance dose and AHS is more controversial. ...
Allopurinol hypersensitivity syndrome (AHS) is a severe and sometimes life-threatening adverse drug reaction. ...A low starting al …
Allopurinol hypersensitivity: Pathogenesis and prevention.
Stamp LK, Chapman PT. Stamp LK, et al. Best Pract Res Clin Rheumatol. 2020 Aug;34(4):101501. doi: 10.1016/j.berh.2020.101501. Epub 2020 Apr 4. Best Pract Res Clin Rheumatol. 2020. PMID: 32265121 Review.
Allopurinol, a first line urate-lowering therapy, has been associated with serious cutaneous reactions that have a high mortality. A number of risk factors for these serious adverse reactions have been identified including ethnicity, HLA-B5801 genotype, kidney impairment, …
Allopurinol, a first line urate-lowering therapy, has been associated with serious cutaneous reactions that have a high mortality. A …
Bullous cutaneous reactions.
Jira M, Amezyane T. Jira M, et al. Pan Afr Med J. 2018 Nov 16;31:188. doi: 10.11604/pamj.2018.31.188.16608. eCollection 2018. Pan Afr Med J. 2018. PMID: 31065326 Free PMC article. No abstract available.
12,080 results
You have reached the last available page of results. Please see the User Guide for more information.